Compounds > dichlororibofuranosylbenzimidazole
Page last updated: 2024-11-07

dichlororibofuranosylbenzimidazole and Leucocythaemia

dichlororibofuranosylbenzimidazole has been researched along with Leucocythaemia in 1 studies

Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Turinetto, V1
Porcedda, P1
Orlando, L1
De Marchi, M1
Amoroso, A1
Giachino, C1

Other Studies

1 other study available for dichlororibofuranosylbenzimidazole and Leucocythaemia

ArticleYear
The cyclin-dependent kinase inhibitor 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole induces nongenotoxic, DNA replication-independent apoptosis of normal and leukemic cells, regardless of their p53 status.
    BMC cancer, 2009, Aug-12, Volume: 9

    Topics: Apoptosis; Cell Line, Tumor; Cells, Cultured; Cyclin-Dependent Kinases; Dichlororibofuranosylbenzimi

2009